Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the market early 2020.

Products, services, technology

Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer.

Location

Wagistrasse 21, 8952 Schlieren, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2010

  • Number of employees in Switzerland

    10-19

Core competencies